‘Encouraging’ early stage results from stem cell therapy trial
Posted on: Monday 15 April 2019
‘Encouraging’ early stage results have been reported from an ongoing clinical trial for a stem cell therapy for retinitis pigmentosa.
Retina UK has welcomed the news, while stressing ‘cautious optimism’ is necessary at this very early and limited stage of testing.
UK-based biotech company ReNeuron Group announced an update on progress with the clinical trial in the US of its hRPC cell therapy earlier this month. The therapy involves injecting stem cells into the back of the patient’s eye.
In February, the Company reported that all three of the first cohort of patients in the study had reported a rapid and significant improvement in vision. It has now confirmed this positive efficacy has been sustained in the first patient cohort in the Phase II part of the study.
Olav Hellebø, Chief Executive Officer of ReNeuron, said: “We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing Phase I/II study with our hRPC cell therapy candidate for retinitis pigmentosa.”
Tina Houlihan, Chief Executive of Retina UK, said: “These early results are encouraging and will provide hope to those living with retinitis pigmentosa. However, while the trial is at this very early stage, with only a very small number of patients involved, we are cautious in our optimism.”
ReNeuron will present and update at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, in Vancouver, Canada, on 26 April 2019.